D
washed twice with cold PBS and lysed with 0.5N NaOH for 6 hours. We next neutralized the lysate with HCl and mixed it with scintillation solution. Relative leucine uptake during the 1-hour period after doxorubicin/vehicle treatment was then calculated (counts per minute).
Immunoblot Analysis
Ventricular tissue (10-30 mg) was homogenized in 700 μL T-PER lysis buffer (Thermo) supplemented with protease inhibitors and phospho-STOP (Roche). Lysates were centrifuged at 8000g (15 minutes) , and the supernatant was used for immunoblotting. For NRVMs, cells were washed once with cold PBS and lysed with T-PER buffer supplemented with protease inhibitors and phospho-STOP. Protein concentration was measured by Bradford assay (BioRad). Protein lysates (10-15 μg) were loaded for electrophoresis and transferred to nitrocellulose membrane. Then, the membrane was processed for immunoblotting and scanning with an Odyssey scanner (LI-COR).
RNA Isolation and Polymerase Chain Reaction Analysis
Total RNA was isolated from ventricular tissue with the Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad). A total of 300 ng RNA was used for reverse transcription and subsequent real-time quantitative polymerase chain reaction analysis (Roche). All primer sequences are provided ( Table I in the online-only Data Supplement).
Long-Lived Protein Degradation Assay
Our protocol was modified from one previously described. 19 To label intracellular proteins, NRVMs were incubated in culture medium supplemented with 0.5 μCi/mL leucine, L- [3,4,5 3 H(N)]-(specific activity, 112 mCi/mmol) for 48 hours at 37°C. Unincorporated radioactive leucine was cleared by washing the cells 3 times with PBS. NRVMs were subsequently incubated for 24 hours with culture medium supplemented with 20 mmol/L leucine (Sigma-Aldrich). The cells were then treated with saline or doxorubicin overnight. Next, medium was removed, and NRVMs were incubated for 3 hours in either Earle balanced salt solution (EBSS) to stimulate autophagy or culture medium. BafA1 was added as a positive control.
At the end of the treatment, 100% trichloroacetic acid was added to the supernatant medium to a final concentration of 10%. The mixture was precipitated overnight, followed by centrifuging for 10 minutes at 2000 rpm (4°C). The acid-soluble radioactivity was measured by liquid scintillation counting with a complete counting cocktail (Research Products International Corp). The cells were washed twice with cold PBS, and protein was precipitated with 10% trichloroacetic acid (30 minutes, 4°C). The precipitant was then washed twice with 95% ethanol and dissolved in 0.5 mol/L NaOH at 37°C overnight. On the next day, 0.5 mol/L HCl was added to neutralize NaOH. Radioactivity was measured by liquid scintillation counting. The rate of long-lived protein degradation was calculated from the ratio of the acid-soluble radioactivity in the medium to that in the acid-precipitated cell fraction.
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Cathepsin Activity
Cathepsin B and cathepsin L activities in living cardiomyocytes were measured with the Magic Red Cathepsin B/L activity kit (Immunochemistry Technologies). With the use of BD FACSCanto II, Cresyl Violet fluorescence was excited with a 561 nm laser, and signal was collected with a 610-nm filter. Fluorescence from doxorubicin was collected with excitation at 488 nm and emission at 710 nm. The geometric mean of the fluorescence signal from excitation/emission of 561/610 nm was calculated and corresponded to cathepsin B or cathepsin L activity. For in vitro cathepsin B/L activity measurements, we used a method described previously. 20 Lysosome-enriched compartments were isolated as described earlier. Protein concentration was measured by Bradford assay, and 5-μg protein lysates from the lysosomal fraction were added to a total of 200 μL reaction buffer (50 mmol/L sodium acetate, 8 mmol/L EDTA, 8 mmol/L dithiothreitol, pH 5.0). Cathepsin B+L activity was measured by the FLUOstar OPTIMA microplate reader (BMG Labtech; excitation, 380 nm; emission, 410±20 nm) after being incubated with the substrate Z-Phe-Arg-AMC (50 μmol/L, Enzo Life Sciences) for 20 minutes (37°C). The cathepsin B inhibitor CA-074 (5 μmol/L, Toris Biosciences) was added in parallel samples to measure cathepsin L activity. The difference between the 2 readings was calculated as cathepsin B activity.
Lysosomal pH Measurement
For qualitative measurement of lysosomal pH, cells were loaded with 2 μmol/L LysoSensor Green DND-189 for 30 minutes (37°C). Then, cells were washed with PBS 3 times and trypsinized for flow cytometry analysis (BD FACS scan, FL1 fluorescence, 10 000 cells collected for each sample).
For quantitative measurement of lysosomal pH, methods were modified from those previously described. 21 Briefly, NRVMs were plated in 35-mm MatTek dishes (MatTek) and loaded with 100 μg/ mL dextran, Oregon Green 514 for 2 days before drug treatment. At the end of doxorubicin treatment, the cells were washed with PBS 3 times and incubated with physiological buffer (136 mmol/L NaCl, 2.5 mmol/L KCl, 2 mmol/L CaCl 2 , 1.3 mmol/L MgCl 2 , 5 mmol/L glucose, 10 mmol/L HEPES, pH 7.4) for 1 hour (37°C) before imaging. Images were acquired with an Andor Spinning Disk confocal microscope with an Apo TIRF 60×/1.49 NA Oil lens, Nikon Ti stand, and Nikon Perfect Focus system. Dextran/Oregon Green 514 was excited at 445 nm and 488 nm; the emitted light was selected with a 525±40-nm filter and captured by an Andor iXon Ultra electron multiplying charge-coupled device camera. Image acquisition was performed with Metamorph version 7.8.6.0. To create a calibration curve, cells were sequentially bathed in isotonic K + solutions (145 mmol/L KCl, 10 mmol/L glucose, 1 mmol/L MgCl 2 , and 20 mmol/L HEPES) with pH ranging from 4.0 to 6.5 and containing 10 μg/mL nigericin (Sigma). The 488/525 and 445/525 fluorescence of each cell was analyzed (Image J Software), and the 488/445 emission fluorescence ratios were plotted as a function of pH fitted to a Boltzmann sigmoid with Prism (GraphPad Software). The ratios of samples were interpolated with the calibration curve. Measurements were performed in 4 independent experiments with 100 to 120 cells in each treatment group.
Lysosomal Reacidification Assay
For the lysosomal reacidification assay, cells grown on coverslips were loaded with dextran, Oregon Green 514 and treated with NS or doxorubicin as described above. Cells were then washed with PBS 3 times and incubated with baseline buffer modified from previous protocols 21 (90 mmol/L K glutamate, 50 mmol/L KCl, 20 mmol/L HEPES, 10 mmol/L glucose, 1 mmol/L EDTA, pH 7.4). Ratiometric fluorescence recordings were performed with the PTI Fluorescence Imaging System (Photon Technology International, Birmingham, NJ) with an automated fluorescence microscope and charge-coupled device camera. The glass coverslip was inserted into the bottom of a perfusion chamber, and images were acquired by exciting dextran, Oregon Green 514 alternately at 440 and 490 nm and recording emitted fluorescence at 510 nm every 10 seconds. 
Histology and Imaging
For red fluorescent protein (RFP)/green fluorescent protein (GFP) analysis, hearts were harvested from anesthetized mice and fixed overnight in 4% paraformaldehyde/PBS. After fixation, hearts were sequentially cryoprotected with overnight incubations in 10% and 18% sucrose. Next, hearts were embedded in freezing matrix (TFM, Triangle Bioscience, Durham, NC), and 8-μm frozen sections were prepared on a Leica CM3000 Cryostat (Leica Microsystems, Buffalo Grove, IL) and stored at −80°C. For NRVMs, cells cultured and treated on coverslips were washed with ice-cold PBS twice and fixed with 4% paraformaldehyde. Before imaging, slides were thawed and counterstained with Prolong-Gold antifade mounting medium (Life Technologies). Images were acquired on a Leica Microsystems TCS SP5 confocal microscope.
Detection of ROS
Anesthetized mice were perfused transcardially with ice-cold heparinized PBS. Hearts were dissected and cryoembedded in TFM. Frozen sections (8 μm) were prepared, and sections were stained with dihydroethidium (Invitrogen) for 15 minutes, followed by sealing with Prolong Gold Antifade Mountant with DAPI. Sections were immediately examined with a Leica DM2000 epifluorescence photomicroscope. Three microscopic fields (6.00×10 4 μm 2 ) were acquired per section, and 3 ventricular sections per mouse were analyzed.
Electron Microscopy
Hearts were transcardially perfused and fixed with 2.5% (vol/vol) glutaraldehyde in 0.1 mol/L sodium cacodylate buffer. After 3 washes with 0.1 mol/L sodium cacodylate buffer, hearts were postfixed in 1% osmium tetroxide and 0.8% K3 [Fe(CN 6 )]/0.1 mol/L sodium cacodylate buffer (1 hour, room temperature). After 3 rinses with water, specimens were dehydrated with increasing concentrations of ethanol, infiltrated with Embed-812 resin, and polymerized in a 60°C oven overnight. Blocks were sectioned with a diamond knife (Diatome) on a Leica Ultracut UC7 ultramicrotome (Leica Microsystems), collected onto copper grids, and poststained with 2% uranyl acetate in water and lead citrate. Images were acquired on a Tecnai G2 spirit transmission electron microscope (FEI) equipped with an LaB6 source (120 kV).
Echocardiography
Echocardiograms were performed on conscious, gently restrained mice (Vevo 2100 system, MS400C probe). M-mode images of the left ventricle were obtained at the level of the papillary muscles. Left ventricular internal diameters at end diastole (LVIDd) and end systole (LVIDs) were measured from M-mode recordings. Fractional shortening was calculated as (LVIDd−LVIDs)/LVIDd (in percent). Six representative contraction cycles were selected for analysis, and average indexes (LVIDd, LVIDs, fractional shortening) were calculated for each mouse.
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E64d, pepstatin (Sigma Aldrich), and concanamycin A (Santa Cruz). Lysotracker Red (DND-99), lysosensor DND-189, acridine orange, and dextran, Oregon Green 514 were purchased from Invitrogen. Antibodies included LC3 (previously developed 22 ), p62 (Abnova), GAPDH (Fitzgerald Industries), pS6 (240/244), S6, pS6K (T389), S6K, p4EBP1, 4EBP1 (Cell Signaling), lysosomal-associated membrane protein (LAMP)-1 (Hybridoma bank), LAMP-2 (Sigma Aldrich), ATP6V0D1, ATP6V0A2, ATPV1D, and ATPV1B2 (Abcam).
Data Analysis
Data were analyzed with Prism software. All data are reported as mean±SEM. The Student t test (2 tailed) was performed to compare 2 groups. One-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups. Repeated-measures ANOVA and subsequent Tukey test were performed to analyze time-course studies among different treatment groups; 2-way ANOVA and subsequent Tukey test were performed to compare groups with different secondary treatments. A value of P<0.05 was considered significant.
Results

Doxorubicin Inhibits Cardiomyocyte Autophagic Flux In Vivo
To study the potential clinical relevance of autophagy in chronic doxorubicin cardiomyopathy, we first set out to develop a preclinical model that mimics the response observed clinically. Our protocol involves 4 once-per-week intravenous administrations of low-dose doxorubicin (5 mg/ kg; Figure IA in the online-only Data Supplement). This dose was selected because the pharmacokinetics of plasma doxorubicin after 1 dose of 5 to 6 mg/kg in mice is comparable to that seen in patients after a standard dose of doxorubicin treatment (60 mg/m 2 ). [23] [24] [25] The intravenous route was favored over an intraperitoneal route for several reasons. First, intraperitoneal administration of doxorubicin elicits injury, leading to peritoneal fibrosis and consequent malaise, anorexia, weight loss, and noncardiac death. Additionally, peritoneal damage is likely to impede drug absorption in ensuing injections. Furthermore, decreased food intake would significantly confound the interpretation of autophagy. Our model, on the other hand, was not marked by morbidity or elevated mortality; mice appeared healthy, consumed normal quantities of food ( Figure IB in the online-only Data Supplement), and gained weight normally ( Figure IC in the online-only Data Supplement). Meanwhile, left ventricular systolic function, tracked by serial echocardiography, manifested progressive declines, reminiscent of the subclinical myocardial dysfunction observed clinically in chronic doxorubicin cardiomyopathy ( Figure ID in the online-only Data Supplement). Long-term follow-up revealed that cardiac function in the doxorubicin group remained depressed for at least 4 months after the last dose was given ( Figure ID in the online-only Data Supplement). For subsequent studies of phenotype, we focused on week 7 (4 weeks after the last dose), when cardiac function had become stable.
To evaluate for changes in autophagic flux, we first quantified markers of autophagy in control (NS-treated) and doxorubicin-treated hearts. Steady-state levels of the autophagy marker LC3-II were increased at 24 hours after doxorubicin injection, persisted to day 3, and eventually returned to baseline by 7 days ( Figure 1A) . Interestingly, the abundance of Beclin 1, a protein involved in autophagosome initiation, manifested similar dynamic changes on doxorubicin treatment ( Figure 1A ). Levels of another protein marker of autophagy, p62/SQSTM1, also increased by 24 hours but returned to baseline by the third day ( Figure 1A ). However, we found that transcript levels of p62/Sqstm1 (but not Lc3b) also increased 24 hours after doxorubicin injection ( Figure 1B ), making it difficult to interpret changes in autophagic flux by tracking p62 protein. Of note, mRNA abundance of several autophagy-related genes, including Beclin 1 and Sqstm1/p62, also increased in the short term, which likely reflects a stress response to doxorubicin ( Figure 1B) .
Increases in steady-state LC3-II levels may derive from activation of autophagic flux or from downstream block of autophagic vacuole processing. To distinguish between these 2 possibilities, we treated mice with intraperitoneal injection of BafA1, an inhibitor of late-stage autophagy. We first examined autophagic flux in heart 24 hours after doxorubicin injection (5 mg/kg), which likely reflects a direct effect of doxorubicin. Treatment of control animals with BafA1 for 2 hours resulted in a significant increase in LC3-II levels, reflecting cardiac autophagic flux under basal conditions ( Figure 1C ). However, doxorubicin-treated animals manifested no increase in LC3-II levels with BafA1 treatment ( Figure 1C ). These data suggest that the accumulation of LC3-II in doxorubicin-treated animals stems from inhibition of LC3-II turnover, implicating a block in autophagic flux.
Examination of autophagic flux at both day 22 (24 hours after the final injection of doxorubicin) and day 28 (7 days after the final injection of doxorubicin) demonstrated that the inhibition of autophagic flux persisted throughout the treatment period and at least 1 week after treatment was suspended ( Figure 1C ). Analysis of longer-term changes in autophagic flux (4 weeks after the last doxorubicin injection) revealed a recovery and even a stimulation of autophagic flux in the doxorubicin-treated hearts ( Figure 1D ). We believe this change, long after cessation of drug administration, likely derives secondary to the remodeling phenotype. In summary, our data suggest that doxorubicin treatment results in a significant block of autophagic flux in heart that occurs within 24 hours of exposure and persists for at least 1 week after exposure. For subsequent mechanistic studies, we chose to focus on 24 hours after a single dose of doxorubicin.
We tested whether starvation, a robust trigger of autophagic flux, could rescue the block in autophagy caused by doxorubicin. Dynamic changes in LC3-II suggested that starvation triggered a strong increase in autophagic flux in the control group, yet the flux remained suppressed in doxorubicin-treated mice ( Figure IIA in the online-only Data Supplement). We also found that starvation induced increases in cardiac p62 transcript abundance (data not shown). Therefore, it was not surprising that p62 protein levels also increased on starvation. However, although BafA1 treatment increased p62 levels in the NS-starvation group, no such effect was seen in the doxorubicin-starvation group ( Figure 
Doxorubicin-Induced Accumulation of Cardiomyocyte Autolysosomes In Vivo
Autophagy is a multistep, dynamic process. To identify the specific point within the autophagic cascade inhibited by doxorubicin, we used an autophagic flux reporter mouse model that harbors an RFP-GFP-LC3 transgene driven by the universally expressed promoter CAG. RFP (pKa 4.5) fluorescence is stable in an acidic environment, but enhanced GFP (pKa 5.9) fluorescence is quenched in the acidic lysosomal compartment. 26 As a consequence, autophagosomes (yellow) can be distinguished from autolysosomes (red), and flux can be tested directly.
Using this reporter, we examined hearts after doxorubicin treatment. Doxorubicin elicited an increase in cardiomyocyte autolysosomes with no significant change in autophagosome numbers (Figure 2A ). Furthermore, BafA1, which inhibits Immunoblotting of LC3, p62, and Beclin 1 in heart lysates and quantifications are shown. n=3 to 5 mice per group. One-way ANOVA followed by the Tukey post hoc test was used to compare doxorubicin-treated animals with control animals. B, Transcript abundance of multiple autophagy-related genes (including p62/Sqstm1) at different time points after doxorubicin treatment. n=3 to 6 mice per group. One-way ANOVA followed by the Tukey post hoc test was used to compare doxorubicin-treated mice with control mice. C, Doxorubicin inhibited cardiac autophagic flux. Bafilomycin A1 (1.5 mg/kg) was administered 22 hours after 1 dose of doxorubicin (5 mg/kg) to assess acute autophagic changes, as well as 22 hours and 7 days after 4 serial doxorubicin injections to assess autophagic changes in a long-term doxorubicin model. Immunoblotting of LC3 is shown. n=4 to 5 per group. Asterisks on the schematics point to time points of assessment of autophagic flux. Two-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups. D, Autophagic flux was increased in mouse hearts 4 weeks after the fourth injection of doxorubicin. n=6 per group. Two-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups. *P<0.05; **P<0.01. autophagosome-lysosome fusion, 27 induced comparable increases in autophagosomes in both the NS-and doxorubicintreated groups; however, a trend remained toward increased autolysosomes in the doxorubicin-treated group relative to controls ( Figure 2A) .
From these data, we can infer 2 immediate conclusions. First, the comparable increase in autophagosomes after BafA1 treatment in both groups excludes the possibility that autolysosome accumulation derives from increased efficiency of autophagosome formation and autophagosome-lysosome fusion, that is, increased autophagy. Second, doxorubicin-elicited accumulation of autolysosomes rather than autophagosomes suggests that the defect in LC3-II turnover induced by doxorubicin occurs at a point downstream of autophagosome-lysosome fusion. Consistent with this notion, transmission electron microscopic studies revealed accumulation of vesicles containing electron-dense content in doxorubicin-treated hearts ( Figure IIB in the online-only Data Supplement), again consistent with increased numbers of lysosomes/autolysosomes. Together, these data suggest a model in which doxorubicin blocks autophagic flux by inhibiting autolysosome turnover.
Doxorubicin Inhibits Autophagic Flux in Cultured Cardiomyocytes
To test the effects of doxorubicin directly on cardiomyocytes, we treated NRVMs with doxorubicin. Suppression of autophagic flux by doxorubicin was dose dependent ( Figure IIIA in the online-only Data Supplement). It has been suggested that doxorubicin concentrations >2 μmol/L do not reflect the clinically relevant context, 28 so we used doxorubicin at 1 μmol/L. Treatment of NRVMs with doxorubicin resulted in a decrease in autophagic flux within 6 hours as measured by LC3-ΙΙ levels, with the maximum effect observed at 18 hours ( Figure 3A ). Doxorubicin decreased both p62/Sqstm1 transcript and protein levels (data not shown); despite this, lysosome inhibition with BafA1 or E46D/PepA failed to restore p62 protein levels in doxorubicin-treated NRVMs ( Figure 3A and Figure Bafilomycin A1 (BafA1; 1.5 mg/kg) was injected intraperitoneally 2 hours before death. Autophagosome (yellow puncta) and autolysosome (red puncta) numbers in heart after doxorubicin/ normal saline (NS) treatment were calculated. n=4 to 5 hearts per group with 6 microscopic fields (14 000 μm 2 ) per heart section analyzed. Scale bar, 20 μm. One-way ANOVA and subsequent Tukey tests were performed for analyzing autophagosome numbers and autolysosome numbers, respectively, among different groups. HPF indicates high-powered field. *P<0.05.
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As a second, independent assessment of autophagy, we measured long-lived protein degradation by pulse-chase analysis. Stimulation of autophagy by starvation increased long-lived protein turnover in NRVMs, and this increase was inhibited in doxorubicin-treated cells ( Figure 3B ). Interestingly, unlike the complete suppression of BafA1-inhibitable LC3-II turnover that we observed by Western blot analysis, doxorubicin only partially blocked wholesale turnover of long-lived proteins. This suggests that doxorubicininduced inhibition of lysosomal degradation may be partial and not complete. Regardless, these data are consistent with an effect of doxorubicin to inhibit autophagic flux in vitro.
To test for generalizability beyond NRVMs, we evaluated autophagic flux in other cell types commonly used to study . In contrast with our in vivo studies, accumulation of steady-state LC3-II was not observed in doxorubicin-treated neonatal cardiomyocytes. However, despite this apparent discrepancy between the in vivo and in vitro results, suppression of autophagic flux was a common finding. We next used a tandem fluorescence RFP-GFP-LC3 reporter system, introduced by lentivirus infection, as an additional monitor of autophagic flux in NRVMs. Consistent with our in vivo data, a significant increase in autolysosome numbers, without changes in autophagosome numbers, was observed after doxorubicin exposure ( Figure 3C ). Transmission electron microscopy revealed accumulation of autolysosomes in doxorubicin-treated cardiomyocytes ( Figure 3D ). In aggregate, our findings lend strong credence to a model in which doxorubicin inhibits autophagic flux in cultured cardiomyocytes at a point downstream of autolysosomal fusion.
Mammalian Target of Rapamycin Complex 1 Activation Is Not Required for DoxorubicinTriggered Block of Autophagic Flux
It is well established that mammalian target of rapamycin complex 1 (mTORC1) inhibits autophagy initiation by phosphorylating ULK1. 29 Furthermore, it has been reported that mTORC1 activity affects lysosomal biogenesis and lysosomal function. 30 For these reasons, we examined whether doxorubicin alters mTORC1 activity in cardiomyocytes. Western analysis of known mTORC1 targets in hearts from doxorubicin-treated mice ( Figure Because glutamine and leucine are the 2 major amino acids that regulate mTORC1 activity, 31 we measured free amino levels after doxorubicin treatment. Intracellular glutamine levels were not altered by doxorubicin ( Figure IVD in the online-only Data Supplement), whereas free leucine levels were decreased (Figure IVE in the online-only Data Supplement). These findings do not, then, explain the upregulation of mTORC1 activity elicited by doxorubicin.
We next examined whether mTOR activity per se was required for the inhibition of autophagic flux that we observed. To test this, we treated NRVMs with Torin 1, a robust and specific inhibitor of mTORC1. As expected, Torin 1 blunted mTORC1 activity ( Figure IVF in the online-only Data Supplement) and increased LC3-II/LC3-I ratios ( Figure IVG and IVH in the online-only Data Supplement), suggesting an increase in autophagy. However, Torin 1 failed to rescue the inhibition of autophagic flux elicited by doxorubicin ( Figure  IVG and IVH in the online-only Data Supplement). This suggests that even though doxorubicin activates mTORC1, doxorubicin-elicited inhibition of autophagy is not dependent on upregulation of mTORC1 activity. It is also worth noting that mTORC2, which is also inhibited by Torin1, is a repressor of autophagy (both macroautophagy 32 and chaperone-mediated autophagy 33 ). Therefore, it is likely that the inhibition of autophagy in cardiomyocytes by doxorubicin is not dependent on mTORC2 activity either.
Doxorubicin Inhibits Lysosome Function by Alkalinizing Lysosomal pH
Our data demonstrate that doxorubicin blocks cardiomyocyte autophagic flux and promotes accumulation of autolysosomes, suggesting that doxorubicin impairs lysosomal degradation at a point downstream of fusion. This observation, coupled with the decrease in long-lived protein turnover in doxorubicintreated cells, led us to examine lysosomal proteolysis in these cells. To pursue this, we measured the activities of cathepsin B and cathepsin L, 2 important lysosomal enzymes, using substrate-based assays. Cresyl Violet (CV) fluorogenic substrates CV-(Arg-Arg) 2 and CV-(Phe-Arg) 2 harbor dipeptides targeted by cathepsin B and cathepsin L, respectively. Nonfluorescent themselves, both substrates are converted to red fluorescent forms after hydrolysis of the 2-peptide sequences. Using flow cytometry of NRVMs treated with vehicle or doxorubicin, we were able to separate the red fluorescence signal elicited by doxorubicin from red fluorescence resulting from substrate cleavage (Figure VA in the online-only Data Supplement). By quantifying the signal from substrate cleavage, we found that doxorubicin triggered decreased activities of both enzymes ( Figure 4A ). In contrast, when we measured cathepsin B/L activities in premade reaction buffer (50 mmol/L sodium acetate, 8 mmol/L EDTA, 8 mmol/L dithiothreitol, pH 5.0), we detected no significant decrease in enzymatic activities after doxorubicin treatment (Figure VB in the online-only Data Supplement). This suggests that the decreased enzymatic activity observed in doxorubicin-exposed cells was not attributable to declines in protein abundance or enzyme dysfunction but rather to changes within the lysosomal environment.
Next, we evaluated lysosome abundance by immunostaining for LAMP-1 and LAMP-2, 2 lysosome-specific markers. We observed that doxorubicin did not alter the intensity of LAMP-1 or LAMP-2 staining (Figure VC in the online-only Data Supplement), suggesting that doxorubicin did not alter lysosome numbers in NRVMs. However, by tracking lysosomes with LysoTracker Red, a fluorescent dye that labels acidic organelles in live cells, we observed that doxorubicin treatment significantly decreased Lysotracker Red puncta ( Figure 4B ). Of note, the fluorescent signals observed in doxorubicin-treated cells were mainly in the nucleus, representing fluorescence from doxorubicin itself ( Figure 4B ). Similar results were seen when acridine orange was used ( Figure VD in the online-only Data Supplement). Together, these data suggest that doxorubicin does not alter lysosome abundance but rather lysosome acidification.
To test this further, we measured lysosomal pH qualitatively using lysosensor DND-189 and flow cytometry. DND-189 emits green fluorescence, the intensity of which increases within an acidic environment. Doxorubicin decreased DND-189 fluorescence in a time-dependent manner, suggesting that doxorubicin decreases lysosome acidity in NRVMs Figure 4C ), which are well established to decrease acidity with the lysosome compartment.
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Next, we measured lysosome pH in cardiomyocytes directly using dextran, Oregon Green 514, a pH-sensitive fluorescent dye conjugated to dextran. This reagent provides a reliable standard curve of pH within the range of 4.0 to 6.5 ( Figure VE in the online-only Data Supplement). As positive controls, brief treatment with BafA1 or NH 4 Cl increased lysosomal pH, as expected ( Figure 4D ). Next, we quantified lysosome pH after doxorubicin exposure, observing that doxorubicin increased lysosomal pH in NRVMs from 4.6 to 5.2 ( Figure 4D ). Together, these data reveal that doxorubicin impairs lysosome acidification.
To test whether changes in lysosome function are specific to doxorubicin or derive nonspecifically from cytotoxicity, we first examined 2 other chemotherapeutic agents known to cause cardiotoxicity: sunitinib and paclitaxel. In NRVMs exposed to either drug overnight, we noted either no change or a slight increases in autophagic flux, depending on the drug concentrations applied (Figure VF in the online-only Data Supplement). With drug concentrations that are more clinically relevant, 36, 37 we tested the effects on lysosomal pH using both DND-189 and dextran, Oregon Green 514. Although some differences were noted between the 2 assays, sunitinib did not increase lysosome pH. Paclitaxel marginally increased lysosomal pH from 4.6 to 4.7, a change that is unlikely to have biological significance ( Figure VG and VH in the online-only Data Supplement).
Doxorubicin Inhibits V-ATPase-Driven Lysosome Acidification
The activities of most lysosomal enzymes are tightly regulated by pH. 38 The acidic luminal environment of the lysosome is attributed mainly to the activity of the V-ATPase. 39 To test the possible effects of doxorubicin on V-ATPase-mediated lysosome acidification, lysosomes were loaded with pH-sensitive dextran and treated with doxorubicin or NS overnight. First, lysosomes were transiently alkalinized by NH 4 Cl-containing buffer, generating intracellular NH 3 , which rapidly diffuses across the cytoplasmic membrane and into lysosomes, where it is protonated and trapped as ammonium ion. 35 Next, reacidification was initiated by removal of NH 4 Cl and concomitant provision of magnesium-containing buffer.
On withdrawal of NH 4 Cl, early recovery of lysosome pH was observed as a result of the release of hydrogen ions by NH 4 + within the lysosome ( Figure 5A ). However, additional recovery of lysosomal pH depends on V-ATPase activity. We observed that lysosomes rapidly reacidified to baseline in NS-treated cardiomyocytes, whereas cells treated with concanamycin A, a specific V-ATPase inhibitor, displayed an initial decrease in lysosomal pH, followed by a failure to reacidify as a result of inhibition of V-ATPase activity ( Figure 4A and 4B) . Consistent with our previous pH measurements, doxorubicin-treated NRVMs displayed increased lysosome pH under baseline conditions ( Figure 4A and 4B) . Furthermore, failure of lysosomes to reacidify after NH 4 Cl washout was observed ( Figure 4A and 4B). These observations suggest that doxorubicin inhibits lysosome acidification through suppression of V-ATPase activity. The V-ATPase complex comprises 14 subunits, assembled into an ATP-hydrolytic domain (V1) and a proton-translocation domain (V0). Energy from ATP hydrolysis within the V1 sector is used to transport protons into the lysosomal lumen through the V0 sector. The association or dissociation of V1 and V0 domains on lysosomes is an important regulatory mechanism of V-ATPase activity. 39 However, we detected no apparent changes in the assembly of V1V0 domains in doxorubicin-treated NRVMs ( Figure 5C ). Figure 5D ). Of note, published work suggests that ATP hydrolysis at the V1 domain of the V-ATPase is essential for amino acid activation of mTORC1. 40 We observed that silencing specific V-ATPase subunits with siRNA abolished the activation of mTORC1 by doxorubicin ( Figure 5D ). This suggests that ATPase hydrolysis is likely intact and argues that uncoupling of V1V0 domains or dysfunction of the V0 domain may underlie suppression of V-ATPase activity in doxorubicin-treated cells.
Importantly, impaired lysosomal acidification elicited by knocking down V-ATPase components increased oxidative stress in NRVMs ( Figure 5E ). This suggests that doxorubicininduced V-ATPase dysfunction and lysosome relative alkalinization could lead to ROS accumulation, a common finding in doxorubicin cardiotoxicity.
Attenuated Autophagy Initiation Protects Against Doxorubicin-Induced Cardiotoxicity
Our findings suggest that doxorubicin impairs autophagic flux by perturbing lysosomal acidification and autolysosomal processing. With no known, effective in vivo approaches to rescue late processing events in the autophagic cascade, we investigated whether changes in autophagic initiation could alter the cardiac response to doxorubicin. Phagophore formation is governed by the class III phosphatidylinositol 3-kinase complex containing Beclin 1, Atg14L, and VPS34. 41 Protein levels and protein-protein binding of Beclin 1 regulate autophagy initiation. 42 Mice with heterozygous deletion of the gene coding for Beclin 1 (Beclin 1 +/− ) display decreased autophagy in multiple tissues, including heart. 22 We capitalized on this model to examine autophagic flux in doxorubicin-treated Beclin 1 +/− mice. Mice were treated with NS or doxorubicin (5 mg/kg) and euthanized 24 hours after injection (±2-hour BafA1 exposure). In contrast to wild-type (WT) mice, which displayed suppression of cardiomyocyte autophagic flux, flux was maintained in Beclin 1 +/− mice after doxorubicin treatment ( Figure 6A ). We tested whether Beclin 1 affects lysosomal pH by knocking down Beclin 1 in NRVMs and measuring lysosomal pH. Beclin 1 knockdown did not rescue the relative alkalinization of the lysosome triggered by doxorubicin exposure, suggesting that the protective effects of Beclin This finding, along with our other data, suggests that doxorubicin suppresses autolysosomal processing but does not completely abolish it. Thus, we posited that the intact autophagic flux in doxorubicin-treated Beclin 1 +/− mice results from diminished demand on the lysosomal system after doxorubicin treatment caused by decreased autophagic initiation in the heterozygous animals. To test this, we crossed Beclin 1 +/− with the autophagy flux reporter mouse line CAG-RFP-GFP-LC3 and quantified the autophagic vacuoles induced by doxorubicin administration. We found that compared with CAG-RFP-GFP-LC3 mice subjected to doxorubicin, Beclin 1
/CAG-RFP-GFP-LC3 mice harbored significantly fewer autolysosomes in heart tissue ( Figure 6B ). These findings are consistent with a model in which Beclin 1 +/− mice maintain normal autophagic flux by decreasing the demand on lysosomal processing.
Our findings suggest a model in which a downstream block in autophagic flux induced by doxorubicin contributes to cardiotoxicity. To determine whether preserved autophagic flux after doxorubicin treatment in Beclin 1-haploinsufficient mice alters doxorubicin-induced cardiac injury, we examined ventricular function in Beclin 1 +/− mice exposed long term to doxorubicin. In contrast to their WT littermates, Beclin 1 +/− mice manifested preserved systolic performance after long-term doxorubicin administration ( Figure 6C ). In addition, Beclin 1 +/− mice manifested less ventricular dilatation provoked by doxorubicin (Table II in 
Enhanced Initiation of Autophagy Exacerbates Doxorubicin Cardiotoxicity
Finally, we examined the cardiac response to doxorubicin in mice with amplified stress-induced cardiomyocyte autophagy from cardiomyocyte-specific overexpression of Beclin 1 (Beclin 1 Tg mice). 22 These mice manifest normal cardiac structure and function under baseline conditions but an amplified autophagic response to disease-related stress. /CAG-RFP-GFP-LC3 24 hours after doxorubicin injection. Autophagosome (yellow puncta) and autolysosome numbers (red puncta) were quantified with 6 microscopic fields (14 000 μm 2 ) per heart section. n=4 mice per group. Scale bar, 20 μm. One-way ANOVA and subsequent Tukey tests were performed for analyzing autophagosome numbers and autolysosome numbers, respectively, among different groups. *P<0.05. C, Cardiac function was preserved in doxorubicin-treated To quantify autophagic flux in doxorubicin-treated heart, we crossed the Beclin 1 Tg mouse line with our autophagy flux reporter line. We observed that reporter mice on the Beclin 1 Tg background harbored higher numbers of autolysosomes relative to WT mice after doxorubicin treatment ( Figure 7B ), suggesting that Beclin 1 Tg mice have exacerbated accumulation of autolysosomes. We also noted an increase in autophagosomes in doxorubicintreated Beclin 1 Tg mouse hearts compared with WT hearts ( Figure 7B ).
To determine whether increased demand on lysosomal processing in Beclin 1 Tg mice resulted in increased susceptibility to doxorubicin-induced cardiomyopathy, we subjected these animals to long-term doxorubicin treatment. Serial echocardiographic analysis revealed that ventricular systolic function declined faster in Beclin 1 Tg mice after doxorubicin treatment compared with WT mice ( Figure 7C ). Cardiac function remained significantly lower in these animals weeks after completion of serial doxorubicin administration ( Figure 7C ). Doxorubicin-treated Beclin 1 Tg mice also manifested exacerbated ventricular dilatation, more robust induction of both fetal genes and fibrotic genes (Table III in 
Discussion
Despite extensive studies of doxorubicin cardiomyopathy, 3 underlying molecular mechanisms remain elusive. The role of autophagy in doxorubicin cardiomyopathy has been probed in recent years but has remained a question of debate. Here, we show that doxorubicin compromises lysosomal acidification and function, thereby inhibiting autophagic flux in cardiomyocytes. This, in turn, is associated with ROS accumulation and pathological cardiac remodeling. We also provide evidence that diminishing autophagic initiation to limit the accumulation of unprocessed autolysosomes ameliorates doxorubicin cardiotoxicity. Conversely, increasing autophagosome formation without correcting the downstream block exacerbates cardiotoxicity (Figure 8 ). Figure 7 Continued. hoc test was used to compare multiple groups; 2-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups. *P<0.05. B, Representative fluorescence images of heart tissue sections from CAG-red fluorescent protein (RFP)-green fluorescent protein (GFP)-LC3 transgenic mice or αMHC-Beclin 1/CAG-RFP-GFP-LC3 mice. Quantification of autophagosome (yellow puncta) and autolysosome numbers (red puncta) was based on 6 microscopic fields (14 000 μm 2 ) per heart section. Scale bar, 20 μm. n=4 mice per group. One-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups for autophagosome numbers and autolysosome numbers, respectively. *P<0.05. C, Cardiac dysfunction was exacerbated in doxorubicin-treated Beclin 1 Tg mice vs WT mice. Representative echocardiograms from WT and Beclin 1 Tg mice treated with normal saline (NS) or doxorubicin at week 7 are shown. Scale bar, 0.1 second, 5 mm. n=8 mice per group. One-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups. *P<0.05, doxorubicin-treated WT mice vs NS-treated WT mice; #P<0.05, doxorubicin-treated Beclin 1 Tg mice vs DOX-treated WT mice. *P<0.05. D, Beclin 1 Tg mice showed exacerbated pathological cardiac remodeling after long-term doxorubicin treatment, examined by relative mRNA levels of fetal genes and fibrotic genes. n=6 per group. Repeated-measures ANOVA followed by the Tukey post hoc test was used to compare multiple groups at each time point. *P<0.05; **P<0.01. E, Doxorubicin-induced reactive oxygen species (ROS) formation (determined by dihydroethidium [DHE] staining of hearts treated with doxorubicin for 20 hours) was increased in Beclin 1 Tg mice. n=4 mice per group. Two-way ANOVA followed by the Tukey post hoc test was used to compare multiple groups. Scale bar, 100 μm. DMSO indicates dimethyl sulfoxide; and HPF, high-powered field. *P<0.05. The Impact of Doxorubicin on Cardiomyocyte Autophagic Flux Previous studies have addressed the possible contribution of changes in autophagic flux to doxorubicin cardiotoxicity; their findings, however, are conflicting. 43, 44 Autophagy has been reported to be either increased [8] [9] [10] [11] [12] or decreased 10,13,14 on the basis of in vivo or in vitro analyses. We suggest that the discrepancies result from several factors. First, a large proportion of the literature is based on short-term, high-dose doxorubicin exposure. These models do not accurately reflect the clinical scenario of chronic doxorubicin cardiomyopathy. Furthermore, intraperitoneal administration, used in the majority of studies, causes local peritoneal injury, which contributes to malaise, anorexia, and cachexia. To address this, we developed a model which involves multiple injections of doxorubicin delivered intravenously at doses used clinically. This, we believe, is a more faithful recapitulation of events seen clinically and avoids the numerous confounding comorbidities that plague other studies.
A second reason for discrepancies in the literature is the lack of evaluation of autophagy as a process of flux. Because autophagy is a dynamic process, a comprehensive evaluation of flux through the cascade is required, as opposed to analyzing a "snapshot in time." Furthermore, evidence reported here and elsewhere 45 indicates that p62, a bona fide autophagic target, is affected transcriptionally by stress (including doxorubicin) and has decreased solubility in some contexts. 46 Indeed, a recent study highlighted the facts that increased levels of p62 could accompany the activation of autophagy and that the presence of p62 is required for autophagic activation in cardiac desminopathy. 47 In our hands, p62 has been less reliable than LC3 as a reflection of autophagic flux in heart. Therefore, sole reliance on the abundance of this protein is likely inadequate to query autophagic flux. Additionally, the use of the tandem fluorescence reporter RFP-GFP-LC3 as a measurement of flux alone could have led to misinterpretation of the accumulation of RFP puncta as increased flux. Our findings highlight the need to examine autophagy and flux with a number of approaches.
Finally, the time point at which autophagic flux is studied varies across studies. Our data uncovered dynamic changes in autophagic flux at different stages of chronic doxorubicin cardiomyopathy. Autophagic flux was blocked 24 hours after a single dose of doxorubicin and remained impaired for days after serial doxorubicin administration, suggesting that inhibition of autophagic flux persists well beyond doxorubicin exposure. However, 4 weeks after the completion of doxorubicin treatments, autophagic flux had recovered and even increased modestly. Thus, whereas inhibition of autophagic flux triggered by doxorubicin is transient, our evidence points strongly to this event as contributing to doxorubicin cardiotoxicity. In our model, progressive declines in cardiac function emerged early while autophagic flux was significantly suppressed.
Interestingly, a lack of pronounced LC3-II accumulation was observed in mice in several scenarios, that is, during longterm doxorubicin treatment, during food deprivation, and in Beclin 1 Tg mice treated with doxorubicin, yet autolysosome accumulation was present. This observation raises the possibility that doxorubicin might also affect autophagic vacuole size, resulting in accumulation of smaller autolysosomes without affecting total LC3-II protein levels. 48 In yeast, Atg8 levels affect autophagosome size but not number. We propose that doxorubicin might affect LC3 recycling and function at the phagophore assembly site. As a consequence, when autophagic initiation is enhanced, by starvation or Beclin 1 overexpression, LC3 levels at the phagophore assembly site fail to keep up, resulting in smaller autophagic vacuoles. However, despite the differences in steady-state LC3-ΙΙ levels at different times (immediately after 1 or 4 doses of doxorubicin) or in different conditions (starvation or Beclin 1 overexpression), suppression of autophagic flux was a uniform finding.
Defect in Lysosomal Digestion Resulting From Impaired Lysosome Acidification
An early clue to localize the locus of impairment in the autophagic cascade derived from our imaging studies, which revealed robust accumulation of autolysosomes. We went on to reveal that doxorubicin inhibits lysosomal acidification and suppresses lysosome function. In fact, early literature reported lysosome changes in cardiomyocytes, in terms of both numbers and morphology, induced by doxorubicin. 1, 49 It has been reported that doxorubicin also increases lysosomal membrane leakage, 50 although the changes seemed to be modest. Our data show for the first time that doxorubicin perturbs lysosomal function via inhibition of its luminal acidity.
Lysosomes are subcellular compartments that harbor a plethora of hydrolases for degradation of proteins, lipids, nucleic acids, and polysaccharides within a low-pH environment. The acidic lysosomal lumen (pH 4-5) is of critical importance for the activities of most hydrolytic enzymes, 38 as well as the movement and maturation of lysosomes. 51 We found that doxorubicin increases lysosomal pH from a basal level of pH 4.6 to 5.2. Given the sensitivity of lysosomal hydrolases to luminal pH, this relative neutralization within the lysosome is likely sufficient to interrupt downstream events in the autophagic cascade.
It has been reported in some cell types that an increase in lysosomal pH can impair the fusion of lysosomes with autophagosomes. 52, 53 In contrast, we observed an increase in autolysosome number triggered by doxorubicin. However, it remains controversial whether inhibition of autophagosome-lysosome fusion is solely dependent on increases in lysosomal pH. Events such as calcium release from the lysosome have been suggested to be required for autophagosome-lysosome fusion. 54 It is also possible that autophagosome-lysosome fusion is inhibited only when lysosomal pH elevates to a certain level. Lastly, when autophagic flux is examined by tandem fluorescent LC3, green fluorescence from enhanced GFP is not quenched when lysosome pH exceeds 6. Therefore, in some instances, the accumulation of "autophagosomes" observed might actually be autolysosomes without an optimal luminal pH. In comparison, we found that doxorubicin raises lysosomal pH to 5.2, a level of acidity sufficient to quench GFP fluorescence, 26 and hence, only RFP fluorescence was detected.
Lysosome V-ATPase
Lysosomal acidification is dependent on the activity of the V-ATPase proton pump. To analyze V-ATPase-induced lysosomal acidification, lysosomes can be transiently alkalinized
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by NH 4 Cl or FCCP. 21, 55 However, lysosomes in NRVMs are relatively resistant to the protonophore FCCP (1 μmol/L); protons dissipate more slowly than reported in other cell lines (data not shown). In contrast, NH 4 Cl induces rapid alkalization in NRVMs. Therefore, we used NH 4 Cl for evaluating the lysosomal reacidification process. Our data strongly suggest that doxorubicin acts by inhibiting V-ATPase activity. However, we cannot exclude contributions from other possibilities such as altered activities of counterion exchangers, increased lysosomal membrane permeability to protons, and inhibition of lysosomal recycling. 56 Mechanisms underlying doxorubicin-dependent inhibition of lysosome V-ATPase activity are presently unknown. We found that proton translocation via the V0 domain of V-ATPase was compromised by doxorubicin; on the other hand, doxorubicin induced mTORC1 activity that was dependent on the intact V-ATPase, suggesting that the V1 domain was hyperactivated by doxorubicin. Evidence collected to date suggests that doxorubicin affects V-ATPase activity through inhibiting the coupling of its 2 domains, V0 and V1. A mutation in vma6, the Atp6v0d homolog in yeast, was shown to uncouple V0 and V1 activities, with compromised proton transport but intact ATPase activity. 57 We did not detect a change in protein levels of the V0d subunit in doxorubicin treatment. However, of note, the V0d subunit is the only protein in the V0 domain localized to the membrane periphery and hence is prone to possible modification by doxorubicin, either directly or secondarily by ROS. Interestingly, it has been shown that oxidative stress can impair V-ATPase function. The proton-pumping function of V-ATPase isolated from calf brain is impaired by hydrogen peroxide. 58 In yeast, a commonly used model for studying V-ATPase activity, a mutant strain exists with normal V-ATPase function in a reductive environment but with impaired V-ATPase function and acidification in an oxidative environment. 59 We believe it is unlikely that doxorubicin targets the V-ATPase specifically in cardiomyocytes, as opposed to lysosome proton pumps in other cells. Rather, because the cardiomyocyte is among the most highly dependent on highthroughput autophagic flux, 60 we suggest that these cells are uniquely susceptible to perturbations in downstream lysosomal processing events. For example, lack of autophagic flux might compromise the ability of cardiomyocytes to eliminate organelles injured by doxorubicin such as mitochondria.
Impaired Autophagy in Doxorubicin Cardiomyopathy
Blockage of autophagic flux in heart has been suggested to play an important role in chloroquine-induced cardiomyopathy. 61 Here, we report that doxorubicin inhibits cardiomyocyte autophagic flux by altering lysosomal function. Because there is no effective means currently available to restore lysosomal function to rescue doxorubicin cardiotoxicity, we modified autophagic flux at the stage of cascade initiation. We used both gain-and loss-of-function models of Beclin 1 activity to alter the rate at which autophagosomes are delivered to the lysosome.
Previous studies reported disparate conclusions on whether autophagy is beneficial or detrimental in doxorubicin cardiotoxicity. Lu et al 8 reported that 3-methyladenine treatment preserved cardiac function after exposure to high-dose doxorubicin. On the other hand, several studies 13, 14 reported that increasing autophagy in mice by either rapamycin or prefasting blunts doxorubicin-induced cardiac dysfunction. However, both starvation and pharmaceuticals such as 3-methyladenine and rapamycin have a wide range of other targets. 62 In contrast, modulating Beclin 1 expression in cardiomyocytes is a more specific means of manipulating autophagy. Although some studies have linked Beclin 1 to apoptotic pathways, 63, 64 we observed minimal apoptotic activity in mouse hearts immediately after doxorubicin injection (data not shown). We further confirmed that Beclin 1 could not rescue lysosomal acidification impaired by doxorubicin in vitro (data not shown). The most plausible explanation for the cardioprotective effects of Beclin 1 haploinsufficiency remains decreased autophagic initiation.
We propose a model in which, by slowing autophagy initiation, the demand on doxorubicin-crippled lysosomes is reduced, allowing more time for the autolysosome to process its cargo. An observation similar to ours was reported in a murine model of Pompe disease: suppressing autophagic initiation in muscle cells reduced glycogen accumulation and restored lysosomal function. 65 Increased cargo load within autolysosomes might further compromise lysosomal function, as seen in lysosomal storage diseases and in aging. 65, 66 Although lysosomal proteolytic function is blunted by doxorubicin, it is not completely abolished. One possibility is that a decrease in demand allows the proper processing of lysosomal content. In addition, the extent of autophagic flux perturbation correlated with the level of doxorubicin-induced ROS production and cardiac dysfunction, lending further support to the notion that restoration of autophagic flux by reducing autophagic initiation protects against doxorubicin cardiotoxicity. Interestingly, another study also pointed to the potential benefit of reducing autophagic initiation and decreasing lysosomal input in attenuating cellular stress in Alzheimer disease. 67 In our study, although doxorubicin-induced inhibition of autophagic flux was short term and reversible, we suggest that the cardiomyocyte injury occurring during this period leads to not only acute cardiac dysfunction but also sustained pathological remodeling.
ROS and Doxorubicin Cardiomyopathy
Despite controversies in this field, accumulation of excess ROS remains widely accepted as a key factor contributing to doxorubicin cardiotoxicity. 7 The potential sites of ROS generation by doxorubicin include mitochondria, sarcoplasmic reticulum, and cytoplasmic compartments. 68 On the other hand, the abundance and activity of the antioxidant enzymes superoxide dismutase and catalase in heart are lower than in other organs. 69 Therefore, high levels of autophagic flux in heart might serve as an important defense mechanism against doxorubicin-induced ROS. 60, 70 Our findings suggest that doxorubicin impairs cardiomyocyte autophagy, therefore compromising cellular defense against ROS-induced cell injury.
At this time, the mechanisms linking autolysosomal accumulation and ROS accumulation remain unclear. The source
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of ROS might be the defective autolysosomes themselves or dysfunctional mitochondria not effectively degraded by autophagy. Damaged mitochondria are a major source for ROS production in cardiomyocytes. 71 At the same time, it has been suggested that lysosomal dysfunction and substrate accumulation also promote ROS production. 72, 73 Intriguingly, whereas persistently high levels of intracellular ROS trigger cellular damage, they can also induce autophagosome formation, 70 potentially initiating a vicious cycle that promotes cell injury.
Conclusions and Perspective
Findings reported here are based on a model that recapitulates the clinical reality of doxorubicin cardiomyopathy. They point to a novel mechanism of doxorubicin cardiotoxicity, that is, relative lysosome alkalinization and consequent inhibition of downstream autophagic flux. By titrating down the initiation of autophagosome initiation, doxorubicin cardiotoxicity is blunted. Together, these data uncover a novel mechanism of disease pathogenesis and point to a unique strategy of limiting myocardial injury. Representative trichrome stain images of hearts from WT and Beclin 1 Tg mice treated with NS and DOX. Beclin 1 Tg mice showed increased perivascular and interstitial fibrosis relative to WT mice after chronic doxorubicin treatment. Scale bar, 100 μm.
